New BCR-ABL mutations detected at the time of progression or dasatinib discontinuation (n = 174). Other progression event indicates loss of complete hematologic response, loss of major cytogenetic response, or increasing white cell count. The progression event was not specified by the investigator for 3 patients who developed M244V, T315I, or V299L. AP indicates accelerated phase; BP, blast phase.